SOURCE: Lipid Sciences

September 20, 2007 08:30 ET

Critical Path Items for Year-End 2007 Highlighted in Presentation at A.G. Edwards' 2nd Annual Emerging Growth Conference

PLEASANTON, CA--(Marketwire - September 20, 2007) - Lipid Sciences, Inc. (NASDAQ: LIPD) -- In a presentation made yesterday at the A.G. Edwards' 2nd Annual Emerging Growth Conference in New York, Dr. S. Lewis Meyer, President and Chief Executive Officer of Lipid Sciences, outlined the timing of critical events for the Company's HDL Mimetic Peptide Development Program, HDL Selective Delipidation clinical trial, and Viral Immunotherapy platform.

Addressing the Company's HDL Mimetic Peptide Development program first, Dr. Meyer noted, "Next week we are set to launch the first in a series of Apo E knockout mouse studies to demonstrate the effectiveness of our synthetic HDL candidate, LSI 518P, in reducing the progression of atherosclerosis in this well-accepted animal model. In November we will begin a study to demonstrate our mimetic peptide's anti-inflammatory properties in a rabbit animal model." Dr. Meyer continued, "The first results of studies assessing the kinetic properties of LSI 518P will be presented by Dr. H. Bryan Brewer, Jr. at the XVI International Symposium on Drugs Affecting Lipid Metabolism (DALM 2007) to be held October 4-7, 2007 in New York. In addition to Dr. Brewer, Drs. Kastelein, Barter, and Sacks, all members of Lipid Sciences' Scientific Advisory Board, will also be presenters at this meeting." The DALM 2007 Symposium is a prestigious gathering of international researchers focusing primarily on the pharmacological control of plasma lipids -- a recognized risk factor in atherosclerosis.

In his presentation, Dr. Meyer also discussed the progress of the Company's HDL Selective Delipidation clinical trial currently being conducted in Washington, D.C. He noted that this safety and feasibility trial will be completed by year end with the results reported out in early 2008. With respect to the Company's Viral Immunotherapy platform, the pre-clinical studies relating to the development of a therapeutic vaccine for HIV will be complete by year end. The results of the "proof of concept" study to develop a preventive vaccine for food animals are also expected before year end. This study is part of a collaborative research and license agreement with Elanco Animal Health, a division of Eli Lilly and Company.

Please log on to to listen to a webcast of this presentation. The webcast and the accompanying slides are also archived on the Company's website: in the Investor Relations section under the News and Events tab.

Lipid Sciences, Inc. is a development-stage biotechnology company engaged in the research and development of products and processes intended to treat major medical indications, in which lipids, or fat components, play a key role. The Company's HDL Therapy platform (HDL Selective Delipidation and HDL Mimetic Peptides) aims to develop treatments to reverse atherosclerosis, a systemic disease of the blood vessels caused by the build-up of cholesterol-filled plaques in the vascular system and, most critically, in the coronary arteries. Regression of such plaques may have a major impact on reducing the risk of acute coronary events. The Company's Viral Immunotherapy platform focuses on the removal of the lipid coatings from lipid-enveloped viruses and other lipid-containing infectious agents by applying Lipid Sciences' proprietary delipidation technologies. The Company believes that removing the virus' protective lipid coating enhances the processing and presentation of viral proteins to stimulate the body's immune system to effectively fight the disease. Conditions that could potentially be impacted by these technologies include HIV, Hepatitis B and Hepatitis C, West Nile, SARS, influenza, and a broad range of animal health applications.

Forward-Looking Statements: This release contains forward-looking statements concerning plans, objectives, goals, strategies, study results, anticipations, expectations, future events or performance as well as all other statements that are not statements of historical fact. The forward-looking statements contained in this release reflect our current beliefs and expectations on the date of this release. Actual results, performance or outcomes may differ materially from what is expressed in the forward-looking statements. Readers should refer to the documents filed by us with the SEC, specifically the most recent reports on Form 10-K and Form 10-Q which identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements. In addition to those risk factors, other factors that could cause actual results to differ materially include the following: Our inability to obtain adequate funds; the significant losses we have incurred to date, and our expectation that we will incur substantial losses in the future; the failure of our technologies to prove safe or effective; our inability to obtain regulatory approval for our technologies, which are only in the clinical development stage; delay or failure to complete pre-clinical animal studies or clinical trials; our inability to add additional clinical trial sites; our dependence on our license agreement with Aruba International B.V.; our reliance on collaborations with strategic partners and consultants; competition in our industry, including the development of new products by others that may provide alternative or better therapies; failure to secure and enforce our intellectual property rights; risks associated with use of biological and hazardous materials; acceptance of our potential products by healthcare providers and patients; our exposure to product liability claims; and our dependence on key personnel.

This release should be read in conjunction with the consolidated financial statements and notes thereto included in our most recent reports on Form 10-K and Form 10-Q. Copies are available through the SEC's Electronic Data Gathering Analysis and Retrieval system (EDGAR) at Lipid Sciences assumes no obligation to update the forward-looking statements included in this document.

Press releases for Lipid Sciences, Inc. are available on our website: If you would like to receive our press releases via email, please contact:

Contact Information

    Deborah S. Lorenz
    Vice President, Investor Relations and
    Corporate Communications
    Lipid Sciences, Inc.
    Email Contact